Concepedia
Statistics
Publications
9
Citations
361
H-Index
Active since
1989
Affiliations
Universität Hamburg(Current)
TUM Klinikum
University Medical Center Hamburg-Eppendorf
Eppendorf (Germany)
K. Burk is an author at Universität Hamburg specializing in pharmacology, medicine, and oncology.
Publications per year
1989–2009
Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results
Cezary Szczylik, Tomasz Demkow, Michael Staehler et al. · Journal of Clinical Oncology · 2007 · 138 citations
Medicine, Oncology, Pharmacotherapy +12
Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma
Claus Bolling, T. Graefe, C. Lübbing et al. · Investigational New Drugs · 2006 · 77 citations
Medicine, Oncology, Pharmacology +11
Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion
R. Thödtmann, Andreas Hüttmann, W.E. Berdel et al. · Investigational New Drugs · 1998 · 33 citations
Medicine, Pharmacokinetics, Pharmacology +8
Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans
K. Mross, U. Mayer, K. Hamm et al. · European Journal of Clinical Pharmacology · 1990 · 27 citations
Pharmacy, Pharmacokinetics, Pharmacology +8
Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611 A study by the AIO groups PHASE-I and APOH
K. Mross, Andreas Hüttmann, Kenneth D. Herbst et al. · Cancer Chemotherapy and Pharmacology · 1996 · 21 citations
1–5 of 9